{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:53:23Z","timestamp":1776786803006,"version":"3.51.2"},"reference-count":184,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2003,1,1]]},"DOI":"10.1080\/09546630305541","type":"journal-article","created":{"date-parts":[[2003,11,25]],"date-time":"2003-11-25T22:21:45Z","timestamp":1069798905000},"page":"30-42","source":"Crossref","is-referenced-by-count":8,"title":["Itraconazole versus terbinafine in the management of onychomycosis: an overview"],"prefix":"10.1080","volume":"14","author":[{"given":"S","family":"Jain","sequence":"first","affiliation":[{"name":"Skin Care Clinic Daryaganj, New Delhi and Dermato\/Venereology (Skin\/VD) Center Panchwati, Azadpur Subzi Mandi, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VN","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Skin Care Clinic Daryaganj, New Delhi and Dermato\/Venereology (Skin\/VD) Center Panchwati, Azadpur Subzi Mandi, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,7,12]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","unstructured":"Zuckerman JM, Tunkel AR, Itraconazole: a new triazole antifungal agent. Infect Control Hasp Epidemiol (1994) 15: 392-410.","DOI":"10.1086\/646938"},{"key":"CIT0002","doi-asserted-by":"crossref","unstructured":"Jain S, Sehgal VN, Itraconazole: an effective oral antifungal for onychomycosis. Int J Dermatol (2001) 40:1-5.","DOI":"10.1046\/j.1365-4362.2001.01039.x"},{"key":"CIT0003","doi-asserted-by":"crossref","unstructured":"Grant SM, Clissold SP, Itraconazole: a review of its pharmaco-dynamic and pharmaco-kinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs (1989) 37:310-44.","DOI":"10.2165\/00003495-198937030-00003"},{"key":"CIT0004","doi-asserted-by":"crossref","unstructured":"Haria M, Bryson HM, Goa KL, Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs (1996) 51:586-619.","DOI":"10.2165\/00003495-199651040-00006"},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"Gupta AK, Sauder DN, Shear NH, Anti-fungal agents: an overview. Part-II\/Am Acad Dermatol (1994) 30:911-33.","DOI":"10.1016\/S0190-9622(94)70112-1"},{"key":"CIT0006","doi-asserted-by":"crossref","unstructured":"Hailey EM, Krakovsky DJ, Rybak MJ, The triazole antifungal agents: a review of Itraconazole and fluconazole. Pharmacotherapy (1990) 10:146-53.","DOI":"10.1002\/j.1875-9114.1990.tb02561.x"},{"key":"CIT0007","doi-asserted-by":"crossref","unstructured":"Balfour JA, Faulda D, Terbinafine: a review of its pharmaco-dynamic and pharmaco-kinetic properties, and therapeutic potential in superficial mycoses. Drugs (1992) 43:259-84.","DOI":"10.2165\/00003495-199243020-00010"},{"key":"CIT0008","unstructured":"Ryder NS, Favre B, Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother (1997) 8: 275-87."},{"key":"CIT0009","doi-asserted-by":"crossref","unstructured":"Jain S, Sehgal VN, Terbinafine, a unique oral anti fungal: current perception. Int J Dermatol (2000) 39:412-23.","DOI":"10.1046\/j.1365-4362.2000.00978.x"},{"key":"CIT0010","doi-asserted-by":"crossref","unstructured":"Gupta AK, Scher RK, DeDoncker P, Current management of onychomycosis. an overview. Dermatol Clin (1997) 15: 121-35.","DOI":"10.1016\/S0733-8635(05)70420-4"},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Vanden Bossche H, Belleno D, Cools W et al, Cytochrome P-450: target for itraconazole. Drug Dev Res (1986) 8: 287-9.","DOI":"10.1002\/ddr.430080133"},{"key":"CIT0012","doi-asserted-by":"crossref","unstructured":"Jain S, Sehgal VN, Onychomycosis: treatment perspective. Int J Dermatol (2000) 39:10-14.","DOI":"10.1046\/j.1365-4362.2000.00882.x"},{"key":"CIT0013","unstructured":"Van Custem J, van Gervan E, The fungicidal activity of itraconazole and terbinafine: in vitro against dermatophytes, in vivo in trichophytosis in guinea pig. World Congress of Dermatology, New York, USA; 12-18 June 1992."},{"key":"CIT0014","doi-asserted-by":"crossref","unstructured":"Ryder NS, Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine anti-mycotic agent. Antimicrob Agents Chemother(1985) 27:252-6.","DOI":"10.1128\/AAC.27.2.252"},{"key":"CIT0015","doi-asserted-by":"crossref","unstructured":"Ryder NS, Squalene epoxidase as the target of antifungal allylamines. Pestic Sei (1987) 21:281-8.","DOI":"10.1002\/ps.2780210405"},{"key":"CIT0016","doi-asserted-by":"crossref","unstructured":"Ryder NS, Mechanism of action and biochemical selectivity of allylamine anti-mycotic agents. Ann N Y Acad Sci (1988) 544:208-20.","DOI":"10.1111\/j.1749-6632.1988.tb40405.x"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Ryder NS, The mechanism of action of terbinafine. Clin Exp Dermatol (1989) 14:98-100.","DOI":"10.1111\/j.1365-2230.1989.tb00900.x"},{"key":"CIT0018","doi-asserted-by":"crossref","unstructured":"Ryder NS, Terbinafine: mode of action and properties of squalene epoxidase inhibition. Br J Dermatol (1992) 126 (suppl 39): 2-7.","DOI":"10.1111\/j.1365-2133.1992.tb00001.x"},{"key":"CIT0019","doi-asserted-by":"crossref","unstructured":"Ryder NS, Dupont M-C, Inhibition of squalene epoxidase by allylamine anti-mycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem J (1985) 230:765-70.","DOI":"10.1042\/bj2300765"},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"Ryder NS, Stuetz A, Nussbaumer P, Squalene epoxidase inhibitors: structural determinants for activity and selectivity of allylamines and related compounds. In: Nes WD, Parish EJ, Trzakos JM (eds) Regulation of isopentenoid metabolism. American Chemical Society: Washington DC, 1992. pp. 192-204.","DOI":"10.1021\/bk-1992-0497.ch014"},{"key":"CIT0021","unstructured":"Ryder NS, Stuetz A, Nussbaumer P, Inhibitors of squalene epoxidase. In: Sandier M, Smith HJ (eds) Design of enzyme inhibitors as drugs, vol 2. Oxford University Press: Oxford, 1994, pp. 3 78-95."},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Gnamusch E, Ryder NS, Paltauf F, Effect of squalene on the structure and function of fungal membranes. J Dermatol Treat (1992) 3:9-13.","DOI":"10.3109\/09546639209088694"},{"key":"CIT0023","doi-asserted-by":"crossref","unstructured":"Van Custom J, van Gerven F, van de Venma et al, Itraconazole a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother (1984) 26: 527-34.","DOI":"10.1128\/AAC.26.4.527"},{"key":"CIT0024","doi-asserted-by":"crossref","unstructured":"Petranyi G, Meingassner JG, Mieth H, Anti-fungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother (1987) 31:1365-8.","DOI":"10.1128\/AAC.31.9.1365"},{"key":"CIT0025","doi-asserted-by":"crossref","unstructured":"Van Custem J, van Gerven F, Janssen PA, Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis (1987) 9: S15-S31.","DOI":"10.1093\/clinids\/9.Supplement_1.S15"},{"key":"CIT0026","doi-asserted-by":"crossref","unstructured":"Clayton YM, Relevance of broad spectrum and fungicidal activity of anti-fungals in the treatment of dermatomycosis. Br J Dermatol (1994) 130 (suppl 43): 7-8.","DOI":"10.1111\/j.1365-2133.1994.tb06084.x"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Leyden J, Pharmaco-kinetic and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol (1998) 38:S42-S7.","DOI":"10.1016\/S0190-9622(98)70483-9"},{"key":"CIT0028","doi-asserted-by":"crossref","unstructured":"Hazen KC, Fungicidal versus fungi-static activity of terbinafine and itraconazole. J Am Acad Dermatol (1998) 38:S37-S41.","DOI":"10.1016\/S0190-9622(98)70482-7"},{"key":"CIT0029","doi-asserted-by":"crossref","unstructured":"Shadomy S, Espinell-Ingroff A, Gebhart RJ, In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia (1985) 23:125-32.","DOI":"10.1080\/00362178585380201"},{"key":"CIT0030","unstructured":"Goudard M, Buffard Y, Ferrari H et al, In vitro spectrum of action of a new anti-fongigue derivative de la naftifine: la terbinafine (SF 86-327). Pathol Biol (Paris) (1986) 34: 680-3."},{"key":"CIT0031","unstructured":"Ahmad A, Khan AK, Sultana S et al, In vitro antifungal studies of terbinafine. Pakistan J Sei Ina\" Res (1989) 32: 737-9."},{"key":"CIT0032","doi-asserted-by":"crossref","unstructured":"Hiratani T, Asagi Y, Yamaguchi H, Evaluation of in vitro anti-mycotic activity of terbinafine, a new allylamine agent. Jpn J Med Mycol (1991) 32: 323-32.","DOI":"10.3314\/jjmm.32.323"},{"key":"CIT0033","unstructured":"Rubio MC, Gil J, Rezusta A et al, In vitro evaluation of three new antifungal agents: amorolfine (RO 144767\/002), terbinafine SF 86-327, and itraconazole (R51, 211). Rev Esp Quimioter (1993) 6:125-39."},{"key":"CIT0034","unstructured":"Venugopal PV, Venugopal TV, Anti-dermatophytic activity of allylamine derivatives. Ind J Pathol Microbiol (1994) 37: 381-8."},{"key":"CIT0035","unstructured":"Venugopal PV, Venugopal TV, Antifungal activity of allylamine derivatives. Ind J Med Res (1994) 99: 71-3."},{"key":"CIT0036","doi-asserted-by":"crossref","unstructured":"Roberts DT, Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Dermatobgy (1997) 194 (suppl 1): 37-9.","DOI":"10.1159\/000246183"},{"key":"CIT0037","doi-asserted-by":"crossref","unstructured":"Ryder NS, Frank I, Interaction of terbinafine with human serum and serum proteins. J Med Vet My col (1992) 33: 451-60.","DOI":"10.1080\/02681219280000611"},{"key":"CIT0038","unstructured":"Janssen T, Xhonneux B, Borgers M et al, An investigation into the antifungal mechanism of action of itraconazole and terbinafine in experimental trichophytosis. Eur J Dermatol (1993) 3:43-9."},{"key":"CIT0039","doi-asserted-by":"crossref","unstructured":"Van Custom J, The in vitro antifungal spectrum of itraconazole. Mycoses (1989) 32 (suppl 1): 7-13.","DOI":"10.1111\/j.1439-0507.1989.tb02290.x"},{"key":"CIT0040","doi-asserted-by":"crossref","unstructured":"Lynch ME, Sobel JD, Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeasts isolates. J Med Vet Mycol (1994) 32:267-74.","DOI":"10.1080\/02681219480000341"},{"key":"CIT0041","unstructured":"Odom FC, Spectrum of orally active anti-fungals. J Eur Acad Dermatol Venereol (1993) 3 (suppl 1): S13."},{"key":"CIT0042","doi-asserted-by":"crossref","unstructured":"Espinel-Infgroff A, Shadomy S. Gebhart RJ, In vitro studies with R 51, 211 (Itraconazole). Antimicrob Agents Chemoiher (1984) 26:5-9.","DOI":"10.1128\/AAC.26.1.5"},{"key":"CIT0043","unstructured":"National Committee for Clinical Laboratory Standards, References method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M 27-P. National Committee for Clinical Laboratory Standards: Villanova. PA. 1992."},{"key":"CIT0044","unstructured":"Ryder NS, Wanger S, Leitner I. In vitro activity of terbinafine against Candida and other yeasts by the NCCLS method. 36th Interscience Conference on Anti-microbial Agents and Chemotherapy. American Society for Microbiology, Washington DC, 15-18 September, 1996: Abstract E 55, 91."},{"key":"CIT0045","unstructured":"Terbinafine effective against Candida. Clinical Courier (1992) 10:10."},{"key":"CIT0046","doi-asserted-by":"crossref","unstructured":"Lebwohl MG, Daniol CR, Leyden J et al, Efficacy and safety of terbinafine for non-dermatophyte and mixed non-dermatophyte and dermatophyte toenail onychomychosis. M J Dermatol (2000) 40: 358-60.","DOI":"10.1046\/j.1365-4362.2001.01204.x"},{"key":"CIT0047","doi-asserted-by":"crossref","unstructured":"Pierard GE, Arrese JE, De Doncker P, Antifungal activity of itraconazole and terbinafine in human stratum corneum. A comparative study. J Am Acad Dermatol (1995) 32: 429-35.","DOI":"10.1016\/0190-9622(95)90064-0"},{"key":"CIT0048","unstructured":"De Doncker P, Arrese J, Jacquim P et al, Itraconazole nail kinetic: the biphasic sequences of diffusion and incorporation is the key to the nail penetration. Am Acad Dermatol 32 (1995) Feb. 4-9."},{"key":"CIT0049","doi-asserted-by":"crossref","unstructured":"Matthieu L, De Doncker P, Cauwenbergh G et al, Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol (1991) 16: 374-6.","DOI":"10.1111\/j.1365-2230.1991.tb00405.x"},{"key":"CIT0050","doi-asserted-by":"crossref","unstructured":"Cauwenbergh G, Degreef H, Heykants J et al, Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol (1988) 18 (suppl 2): 263-8.","DOI":"10.1016\/S0190-9622(88)70037-7"},{"key":"CIT0051","unstructured":"De Doncker P, Pharmaco-kinetic in onychomycosis. In: Jacobs P, Nail L (eds) Selected topics in medical mycology. M. Dekker: (2002; in press)."},{"key":"CIT0052","doi-asserted-by":"crossref","unstructured":"Munro CS, Shuster S, The route of rapid access of drugs to the distal nail plate. Acta Derm Venereal (1992) 72: 387-8.","DOI":"10.2340\/0001555572387388"},{"key":"CIT0053","doi-asserted-by":"crossref","unstructured":"Faergemann J, Zehender H, Jones T et al, Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hairs, sebum and eccrine sweat. Acta Derm Venereal (1990) 70: 322-6.","DOI":"10.2340\/0001555571322326"},{"key":"CIT0054","doi-asserted-by":"crossref","unstructured":"Faergemann J, Zehender H, Denouel J et al, Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hairs and nails during and after 2 50-mg terbinafine orally once per day for4 weeks. Acta Derm Venereal (1993) 73: 305-9.","DOI":"10.2340\/000155557300304"},{"key":"CIT0055","doi-asserted-by":"crossref","unstructured":"Faergemann J, Zehender H, Millereioux L, Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair, and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol (1994) 19:121-6.","DOI":"10.1111\/j.1365-2230.1994.tb01138.x"},{"key":"CIT0056","doi-asserted-by":"crossref","unstructured":"Faergemann J, Zehender H, Boukhabza A et al, A double blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair, and nails during and after oral medication. Acta Derm Venereal (1997) 77: 74-6.","DOI":"10.2340\/00015555777476"},{"key":"CIT0057","doi-asserted-by":"crossref","unstructured":"Finlay AY, Pharmaco-kinetics of terbinafine in the nail. Br J Dermatol (1992) 126 (suppl 39): 28-32.","DOI":"10.1111\/j.1365-2133.1992.tb00006.x"},{"key":"CIT0058","doi-asserted-by":"crossref","unstructured":"Finlay AY, Pharmaco-kinetics of terbinafine in the nail. J Dermatol Treat (1992) 3 (suppl 1): 15-17.","DOI":"10.3109\/09546639209088695"},{"key":"CIT0059","doi-asserted-by":"crossref","unstructured":"Finlay AY. Lever L, Thomas R et al, Nail matrix of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat (1990) 1 (suppl 2): 51-3.","DOI":"10.3109\/09546639009089035"},{"key":"CIT0060","doi-asserted-by":"crossref","unstructured":"Willemsen M, De Doncker P, Willems J et al. Post treatment itraconazole levels in the nail. J Am Acad Dermatol (1992) 26:731-5.","DOI":"10.1016\/0190-9622(92)70102-L"},{"key":"CIT0061","doi-asserted-by":"crossref","unstructured":"Roseeuw D, De Doncker P, New approaches to the treatment of onychomycosis. J Am Acad Dermatol (1993) 29: S45-S50.","DOI":"10.1016\/S0190-9622(08)81837-3"},{"key":"CIT0062","doi-asserted-by":"crossref","unstructured":"Schatz F, Brautigam M, Dobrowolski E et al, Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol (1995) 20: 377-83.","DOI":"10.1111\/j.1365-2230.1995.tb01353.x"},{"key":"CIT0063","doi-asserted-by":"crossref","unstructured":"Zehender H, Cabiac MD, Denouel J et al, Elimination kinetics of terbinafine from human plasma and tissues following multiple dose administration, and comparison with 3 main metabolites. Drug Invest (1994) 8:203-10.","DOI":"10.1007\/BF03258479"},{"key":"CIT0064","doi-asserted-by":"crossref","unstructured":"Kovarik JM, Mueller EA, Zehender H et al, Multiple dose pharmaco-kinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother (1995) 39: 2738-41.","DOI":"10.1128\/AAC.39.12.2738"},{"key":"CIT0065","doi-asserted-by":"crossref","unstructured":"Goodfield MJD, Andrew L, Evans EGV, Short-term treatment of dermatophyte onychomycosis with terbinafine. Br J Dermatol (1992) 126 (suppl 39): 33-5.","DOI":"10.1111\/j.1365-2133.1992.tb00007.x"},{"key":"CIT0066","unstructured":"Haneke F, Delescluse J, Pinack EPB, The use of itraconazole in onychomycosis: a review. Eur ] Dermatol (1996) 6: 7-10."},{"key":"CIT0067","doi-asserted-by":"crossref","unstructured":"Baudraz-Rosselet F, Rakosi T, WiIi PB et al, Treatment of onychomycosis with terbinafine. Br J Dermatol (1992) 126 (suppl 39): 40-6.","DOI":"10.1111\/j.1365-2133.1992.tb00009.x"},{"key":"CIT0068","doi-asserted-by":"crossref","unstructured":"Van der Schroeff JG, Girkel PKDS, Crijns MB et al, A randomized treatment duration finding study of terbinafine in onychomycosis. Br J Dermatol (1992) 126 (suppl 39): 36-9.","DOI":"10.1111\/j.1365-2133.1992.tb00008.x"},{"key":"CIT0069","doi-asserted-by":"crossref","unstructured":"Arenas R, Domingruez-Cherit J, Fernandez LMA, Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol (1995) 34:138-43.","DOI":"10.1111\/j.1365-4362.1995.tb03600.x"},{"key":"CIT0070","doi-asserted-by":"crossref","unstructured":"Brautigam M, Nolting S, Schopf RE et al, Randomized double blind comparison of terbinafine for itraconazole for treatment of toenail tinea infection. Br Med J (1995) 311: 919-22.","DOI":"10.1136\/bmj.311.7010.919"},{"key":"CIT0071","doi-asserted-by":"crossref","unstructured":"Hay RJ, Clayton YM, Moore MK et al, An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol (1988) 119: 359-66.","DOI":"10.1111\/j.1365-2133.1988.tb03229.x"},{"key":"CIT0072","doi-asserted-by":"crossref","unstructured":"Walsoe I, Stangerup M, Svejgaard E, Itraconazole in onychomycosis: open and double blind studies. Acta Derm Venereal (1990) 70:137-40.","DOI":"10.2340\/0001555570137140"},{"key":"CIT0073","doi-asserted-by":"crossref","unstructured":"Plepponen T, Blornovist K, Brandt H et al, Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother (1992) 29:195-205.","DOI":"10.1093\/jac\/29.2.195"},{"key":"CIT0074","doi-asserted-by":"crossref","unstructured":"Korting HC, Schafer-Korung M, Zieniche H et al, Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin, compared with that of itraconazole. Antimicrob Agents Chemother (1993) 37:2064-8.","DOI":"10.1128\/AAC.37.10.2064"},{"key":"CIT0075","doi-asserted-by":"crossref","unstructured":"Arenas R, Fernandez G, Dominguez L, Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical anti-mycotic or keratolytic agent. Int J Dermatol (1991) 30: 586-9.","DOI":"10.1111\/j.1365-4362.1991.tb02648.x"},{"key":"CIT0076","doi-asserted-by":"crossref","unstructured":"Zaias N, Serrano L, The successful treatment of finger Tnchophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol (1989) 14:120-3.","DOI":"10.1111\/j.1365-2230.1989.tb00907.x"},{"key":"CIT0077","doi-asserted-by":"crossref","unstructured":"Goodfield MJ, Rowell NR, Forster RA et al, Treatment of dermatophyte infection of the finger- and toe nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agents. Br J Dermatol (1989) 121: 753-7.","DOI":"10.1111\/j.1365-2133.1989.tb08217.x"},{"key":"CIT0078","unstructured":"Rakosi T, Terbinafine and onychomycosis. Dermatologica (1990) 181:174 (abstract)."},{"key":"CIT0079","doi-asserted-by":"crossref","unstructured":"Goodfield MJ, Clinical results with terbinafine in onychomycosis. J Dermatol Treat (1990) 1: 55-7.","DOI":"10.3109\/09546639009089036"},{"key":"CIT0080","unstructured":"Eastcott DF, Terbinaflne and onychomycosis. N Z Med J (1991) 104:17 (letter)."},{"key":"CIT0081","unstructured":"Cribier B, Grosshans E, Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses. Ann Dermatol Venereal (1994) 121:15-20."},{"key":"CIT0082","doi-asserted-by":"crossref","unstructured":"Haneke E, Tausch I Brautigam M et al, LAGOS III group. Short-duration treatment of fingernail dermatophytosis: a randomized, double blind study with terbinafine and griseofulvin. J Am Acad Dermatol (1995) 32: 72-7.","DOI":"10.1016\/0190-9622(95)90187-6"},{"key":"CIT0083","doi-asserted-by":"crossref","unstructured":"Faergemann J, Anderson C, Hersle K et al, Double blind, parallel group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol (1995) 32:750-3.","DOI":"10.1016\/0190-9622(95)91454-4"},{"key":"CIT0084","doi-asserted-by":"crossref","unstructured":"Galimberti R, Kowalczyk A, Flores V et al, Onychomycosis treated with a short course of oral terbinafine. Int Dermatol (1996) 35:374-5.","DOI":"10.1111\/j.1365-4362.1996.tb03645.x"},{"key":"CIT0085","doi-asserted-by":"crossref","unstructured":"Hoffman H, Brautigam M, Weldinger G et al, Treatment of toenail onychomycosis: a randomized double blind study with terbinafine and griseofulvin. Arch Dermatol (1995) 131:919-22.","DOI":"10.1001\/archderm.131.8.919"},{"key":"CIT0086","doi-asserted-by":"crossref","unstructured":"Velthuis PJ, Nijenhuis M, Treatment of onychomycosis with terbinafine in patients with Down's syndrome. Br J Dermatol (1995) 133:144-5.","DOI":"10.1111\/j.1365-2133.1995.tb02513.x"},{"key":"CIT0087","doi-asserted-by":"crossref","unstructured":"Watson A, Marley J, Ellis D, Williams T, Terbinafine in onychomycosis of toe nail: a novel treatment protocol. J Am Acad Dermatol (1995)33: 775-9.","DOI":"10.1016\/0190-9622(95)91815-9"},{"key":"CIT0088","doi-asserted-by":"crossref","unstructured":"Tausch I, Brautigam M, Weidinger G, Jones TC, Lagos V study group. Evaluation of six week treatment of terbinafine in tinea unguium in a double blind trial comparing 6 and 12 weeks therapy. The LAGOS study group. Br J Dermatol(1997) 136: 737-42.","DOI":"10.1111\/j.1365-2133.1997.tb03662.x"},{"key":"CIT0089","doi-asserted-by":"crossref","unstructured":"Watson AO, Harley J, Ellis D et al, Long term follow up of patients with toenail onychomycosis after treatment with terbinafine. Australas J Dermatol (1998) 39:29-30.","DOI":"10.1111\/j.1440-0960.1998.tb01237.x"},{"key":"CIT0090","doi-asserted-by":"crossref","unstructured":"Svejgaard EL, Brandrup F, Kragablle K et al, Oral terbinafine in toenail dermatophytosis. A double blind placebo-controlled multi-centre study with 12 months follow-up. Acta Derm Venereal (1997) 77:66-9.","DOI":"10.2340\/0001555555776669"},{"key":"CIT0091","unstructured":"Drake LA, Shear NH, Ariette JP et al, Oral terbinafine in the treatment of toenail onychomycosis: North American multi-centre trial. J Am Acad DermatoI (1997) 37: 740-5."},{"key":"CIT0092","doi-asserted-by":"crossref","unstructured":"De Backer M, De Keyser P, De Vroey C et al, 12 week treatment for dermatophyte toe onychomycosis: terbinafine 2 50 mg\/day vs itraconazole 200 mg\/day - double blind comparative trial. Br J Dermatol (1996) 134(suppl 46): 16-17.","DOI":"10.1111\/j.1365-2133.1996.tb15653.x"},{"key":"CIT0093","unstructured":"Andre J, Havu V, European experience with itraconazole pulse therapy in the treatment of toenail onychomycosis. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy; 28-29 September 1995, pp. 22-5."},{"key":"CIT0094","unstructured":"Ginter G, Antifungal pulse therapy in toe nail onychomycosis. Austrian experience. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy; 28-29 September 1995, pp. 26-7."},{"key":"CIT0095","unstructured":"Elewski B, Itraconazole pulse therapy for the treatment of fingernail onychomycosis. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy; 28-29 September 1995, pp. 28-30."},{"key":"CIT0096","unstructured":"Haneke E, Ring J, Schrooten M et al, Itraconazole in the treatment of onychomycosis: an open, multi-centre trial to investigate the efficacy and safety of itraconazole pulse therapy. Janssen Research Foundation Research Report ITR-GER-18, April 1995."},{"key":"CIT0097","unstructured":"Havu V. De Doncker P, Joosen H et al. Effect of itraconazole in the treatment of onychomycosis of toenails. A randomized, double-blind trial comparing continuous treatment with pulse therapy. Janssen Research Foundation Report ITR-FIN-1, March 1995."},{"key":"CIT0098","unstructured":"Zaiag N, Elewski B, Scher R et al, Effect of itraconazole intermittent therapy in the treatment of onychomycosis of fingernails. A randomized, double blind comparison with placebo. Janssen Research Foundation Clinical Research Report ITR-USA-71, April 1995."},{"key":"CIT0099","unstructured":"Decroix J, De Doncker P, Cornwell L et al, Itraconazole in the treatment of onychomycosis: an open, randomized trial to evaluate the efficacy and tolerability of three or four month intermittent therapy with itraconazole. Janssen Research Foundation Clinical Research Report ITR-BEL-43,March 1995."},{"key":"CIT0100","unstructured":"De Doncker P, Van Lint J, Dockx P, Reseeuw D, Pulse therapy with one weekly itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis (1995) 56:180-3. Shortened regime of 200 mg b.i.d. X 7 days\/month for 2 or 3 months. Janssen Clinical Research Report N111629 M. 1995, pp. 1-44."},{"key":"CIT0101","doi-asserted-by":"crossref","unstructured":"De Doncker P, Decroix J, Pierard GE et al, Antifungal pulse therapy for onychomycosis. A pharmaco-kinetic and pharmaco-dynamic investigation of monthly cycles of 1week pulse therapy with itraconazole. Arch Dermatol (1996) 132:34-41.","DOI":"10.1001\/archderm.132.1.34"},{"key":"CIT0102","unstructured":"Haneke E, Ring J, Ta Erbashi D et al, Efficacy and safety of itraconazole 1-week pulse therapy in the treatment of onychomycosis: an open, German multi-centre trial. Poster presented at the 54th Annual Meeting of the American Academy of Dermatology, Washington DC; 10-15 February 1996."},{"key":"CIT0103","unstructured":"Andre J, De Doncker P, Ginter G et al, Intermittent pulse therapy with itraconazole in onychomycosis: an update. Poster presented at the 54th Annual Meeting of the American Academy of Dermatology, Washington DC; 10-15 February 1996."},{"key":"CIT0104","doi-asserted-by":"crossref","unstructured":"Del Rosso JQ, Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. J Am Osteopath Assoc (1996) 96:607-9.","DOI":"10.7556\/jaoa.1996.96.10.607"},{"key":"CIT0105","unstructured":"Li WD, Ping WA, Yu LR et al, Therapeutic efficacy of intermittent pulse therapy with itraconazole in onychomycosis. A Chinese multi-centre trial. Poster presented at the 54th Annual Meeting of the American Academy of Dermatology, Washington DC; 10-15 February 1996."},{"key":"CIT0106","doi-asserted-by":"crossref","unstructured":"Doncker PD, Gupta AK, Marynissen G et al, Itraconazole pulse therapy for onychomycosis and dermato-mycosis: an overview. J Am Acad DermatoI (1997) 37:969-74.","DOI":"10.1016\/S0190-9622(97)70074-4"},{"key":"CIT0107","doi-asserted-by":"crossref","unstructured":"Bonifaz A, Carrasco Gerrard E, Saul A, Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol (1997) 36:70-2.","DOI":"10.1046\/j.1365-4362.1997.00025.x"},{"key":"CIT0108","doi-asserted-by":"crossref","unstructured":"Wu J, Wen H, Liao W, Small dose itraconazole pulse therapy in the treatment of onychomycosis. Mycoses (1997) 40(9-10): 39 7-400.","DOI":"10.1111\/j.1439-0507.1997.tb00258.x"},{"key":"CIT0109","doi-asserted-by":"crossref","unstructured":"Odom RB, AIy R, Scher RK et al, A multi-centre, placebo controlled, double blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol (1997) 36:231-5.","DOI":"10.1016\/S0190-9622(97)70286-X"},{"key":"CIT0110","doi-asserted-by":"crossref","unstructured":"De Doncker P, Scher RK, Baran RL et al, Itraconazole therapy is effective for pedal onychomycosis caused by some non dermatophyte molds and in mixed infection with dermatophytes and molds: a multi-centre study with 36 patients. J Am Acad Dermatol (1997) 36:173-7.","DOI":"10.1016\/S0190-9622(97)70275-5"},{"key":"CIT0111","doi-asserted-by":"crossref","unstructured":"Heikkila H, Stubb S, Long term results of patients with onychomycosis treated with itraconazole. Acta Derm Venereol (1997) 77:70-1.","DOI":"10.2340\/00015555777071"},{"key":"CIT0112","doi-asserted-by":"crossref","unstructured":"Havu V, Brandt H, Heikkila H et al, A double blind randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toenail onychomycosis. Br J Dermatol (1997) 136:230-4.","DOI":"10.1111\/j.1365-2133.1997.tb14902.x"},{"key":"CIT0113","unstructured":"Kullavanijaya P, Ungpakron R, Rengchinam S, Itraconazole in the treatment of onychomycosis; an open randomized trial to evaluate the efficacy and tolerability of intermittent therapy with itraconazole. Poster presented at the Clinical Dermatology (2000), Singapore (1998); 18-20 June."},{"key":"CIT0114","doi-asserted-by":"crossref","unstructured":"Gupta AK, De Doncker P, Scher RK et al, Itraconazole in the treatment of onychomycosis: an overview. Int J Dermatol (1998) 37: 303-8.","DOI":"10.1046\/j.1365-4362.1998.00360.x"},{"key":"CIT0115","doi-asserted-by":"crossref","unstructured":"Schuster S, Munro CS, Single dose treatment of fungal nail disease. Lancet (1992) 339:1066.","DOI":"10.1016\/0140-6736(92)90595-T"},{"key":"CIT0116","doi-asserted-by":"crossref","unstructured":"Alpsoy E, Yilmaz E, Basaran E, Intermittent therapy with terbinafine for dermatophyte toe onychomycosis: a new approach. J Dermatol (1996) 23:259-62.","DOI":"10.1111\/j.1346-8138.1996.tb04009.x"},{"key":"CIT0117","doi-asserted-by":"crossref","unstructured":"Tosu A, Piraccini BM, Sunchi C et al, Treatment of dermatophyte nail infection: an open randomized trial comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol (1996) 34: 595-600.","DOI":"10.1016\/S0190-9622(96)80057-0"},{"key":"CIT0118","doi-asserted-by":"crossref","unstructured":"Hay RJ, Baran R, Moore MK et al, Candida onychomycosis: an evaluation of the role Candida species in nail disease. Br J Dermatol (1988) 118:47-58.","DOI":"10.1111\/j.1365-2133.1988.tb01749.x"},{"key":"CIT0119","unstructured":"Kagawa S, A clinical evaluation of itraconazole: a new oral antifungal agent in the treatment of tinea unguium, Candida onychomycosis, and Candida onychia\/paronychia. Clin Rep (1991) 25:433-48."},{"key":"CIT0120","unstructured":"Tosu A, Piraccini BM, Vincenzi C et al, Itraconazole in the treatment of chronic mucocutaneous candidiasis in childhood. Poster presented at the 54th Annual Meeting of the American Academy of Dermatology, Washington DC; 10-15 February 1996."},{"key":"CIT0121","unstructured":"Rashid A, De Doncker P, Pulse dose regimen of oral itraconazole in the treatment of Candida paronychia. International Summit on Cutaneous Antifungal Therapy Programme, Vancouver BC, Canada; May 1990; Abstract 5 5."},{"key":"CIT0122","doi-asserted-by":"crossref","unstructured":"Roberts DT, Richardson MD, Dwyer PK, Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat (1992) 3 (suppl): 39-42.","DOI":"10.3109\/09546639209088701"},{"key":"CIT0123","unstructured":"Segal R, Guadelli L, Kritzmann A et al, Treatment of Candida nail infection with terbinafine. Presented at the 2nd Annual International Summit on Cutaneous Antifungal Therapy, Boston, MA; 10-13 November 1994."},{"key":"CIT0124","doi-asserted-by":"crossref","unstructured":"Segal R, Kritzmann A, Cividalli L et al, Treatment of Candida nail infections with terbinafine. J Am Acad Dermatol (1996) 35:958-61.","DOI":"10.1016\/S0190-9622(96)90120-6"},{"key":"CIT0125","doi-asserted-by":"crossref","unstructured":"Nolting S, Brautigam M, Weidinger G, Terbinafine in onychomycosis with involvement by non-dermatophyte fungi. Br J Dermatol (1994) 130 (suppl 43): 16-21.","DOI":"10.1111\/j.1365-2133.1994.tb06088.x"},{"key":"CIT0126","doi-asserted-by":"crossref","unstructured":"Jung EG, Haas PJ, Brautigam M et al, Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses (1994) 37:361-5.","DOI":"10.1111\/myc.1994.37.9-10.361"},{"key":"CIT0127","unstructured":"Pierard GE, Itraconazole in the treatment of onychomycosis caused by non-dermatophytes. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy; 28-29 September 1995; pp. 33-4."},{"key":"CIT0128","unstructured":"De Doncker P, Efficacy of itraconazole in the treatment of non-dermatophyte onychomycosis of the toenail. 54th Annual Meeting of the American Academy of Dermatology, Washington DC, USA; 10-15 February 1996."},{"key":"CIT0129","unstructured":"De Doncker P, Efficacy of itraconazole pulse therapy for the treatment of non-dermatophyte onychomycosis of the toenail. Poster presented at the 3rd International Symposium on Cutaneous Fungal, Bacterial, and Viral Infection and Therapy, San Francisco, CA, USA; 14-17 September 1995."},{"key":"CIT0130","doi-asserted-by":"crossref","unstructured":"Cox NH, Irving B, Cutaneous 'ringworm' lesions of Scopulariopsis brevicaulis. Br J Dermatol (1993) 129: 726-8.","DOI":"10.1111\/j.1365-2133.1993.tb03341.x"},{"key":"CIT0131","doi-asserted-by":"crossref","unstructured":"Tosu A. Piraccini BM, Stinchi C et al, Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic anti-fungals. Br J Dermatol (1996) 135: 799-802.","DOI":"10.1111\/j.1365-2133.1996.tb03895.x"},{"key":"CIT0132","unstructured":"Robert DT, The clinical efficacy of terbinaflne in the treatment of fungal infections of the nails. Rev Contemp Pharmacokinet (1997) 8:299-312."},{"key":"CIT0133","unstructured":"Degreef H, Randomized, double blind trial on the efficacy and tolerability of itraconazole 200 mg compared with terbinafine 2 50 mg in the treatment of onychomycosis of the toenail. Clinical Research Report ITR-INT-17, May 1996."},{"key":"CIT0134","doi-asserted-by":"crossref","unstructured":"Brautigam M, Nolting S, Schopf RE et al, German randomized, double multi-centre comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br J Dermatol (1996) 134:18-21.","DOI":"10.1111\/j.1365-2133.1996.tb15654.x"},{"key":"CIT0135","doi-asserted-by":"crossref","unstructured":"Brautigam M, Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. J Am Acad Dermatol (1998) 38: S53-S6.","DOI":"10.1016\/S0190-9622(98)70485-2"},{"key":"CIT0136","doi-asserted-by":"crossref","unstructured":"De Backer M, De Vroey C, Lesaffre E et al, Twelve weeks of continuous oral therapy for toenail onychomycosis caused is dermatophytes. A double blind comparative trial of terbinafine 250 mg\/day versus itraconazole 200 mg\/day. J Am Acad Dermatol (1998) 38: S57-S63.","DOI":"10.1016\/S0190-9622(98)70486-4"},{"key":"CIT0137","doi-asserted-by":"crossref","unstructured":"Evans EG, Sigurgeirsson B, Double blind randomized study of continuous terbinafine compared with intermitted itraconazole in the treatment of toenail onychomycosis, The LIOH study group. Por J Med (1999) 318:1031-5.","DOI":"10.1136\/bmj.318.7190.1031"},{"key":"CIT0138","doi-asserted-by":"crossref","unstructured":"Birbaum JE, Concluding remarks. Dermatology (1997) 194 (suppl 1): 48-9.","DOI":"10.1159\/000246187"},{"key":"CIT0139","doi-asserted-by":"crossref","unstructured":"Schuster S, Onychomycosis: making sense of the assessment of antifungal drugs. Acta Derm Venereal (1998) 78: 1-4.","DOI":"10.1080\/00015559850135724"},{"key":"CIT0140","unstructured":"Johnson RA, The year book of dermatology (1997) Sober AJ, Fitzpatrick TB. (eds) Mosby: St Louis, 1997, pp. 175-6."},{"key":"CIT0141","unstructured":"Hay RJ, Safety of antifungal pulse therapy. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy; 28-29 September 1995."},{"key":"CIT0142","unstructured":"Cauqenberg G, Legendre R, Blatchford N, Itraconazole a novel oral antifungal. Its efficacy and safety profile. 8th Regional Conference of Dermatology, HaIi, 16-20 June."},{"key":"CIT0143","doi-asserted-by":"crossref","unstructured":"Perfect JR, Lindsay MH, Drew RH, Adverse drug reactions to systemic anti-fungals: prevention and management. Drug Saf (1992) 7:323-63.","DOI":"10.2165\/00002018-199207050-00003"},{"key":"CIT0144","doi-asserted-by":"crossref","unstructured":"Tucker RM, Hag Y, Denning DW et al, Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 26: 561-6.","DOI":"10.1093\/jac\/26.4.561"},{"key":"CIT0145","unstructured":"De Bente K, Lubin G, Cauvenbergh G, Safety aspects of itraconazole therapy in vaginal, candidosis, dermatomycosis, and onychomycosis. A review. Curr Ther Res (1991) 49:814-22."},{"key":"CIT0146","doi-asserted-by":"crossref","unstructured":"Restrepo A, Robledo J, Gomez I et al, Itraconazole therapy in lymphangitis and cutaneous sporotrichosis. Arch Dermatol (1986) 122:413-17.","DOI":"10.1001\/archderm.122.4.413"},{"key":"CIT0147","doi-asserted-by":"crossref","unstructured":"Collazos J, Mayo J, Mart Inez E et al, Unusual liver toxicity due to the new antifungal agents fluconazole and itraconazole. Int Hepatol Commun (1995)3:112.","DOI":"10.1016\/0928-4346(94)00163-Y"},{"key":"CIT0148","doi-asserted-by":"crossref","unstructured":"Gallardo Quesada S, Luel'mo Aguilar J, GuanyabensCalvet C, Hepato-toxicity associated with itraconazole (letter). Int J Dermatol (1995) 34: 589.","DOI":"10.1111\/j.1365-4362.1995.tb02962.x"},{"key":"CIT0149","unstructured":"Lavrijsen AP, Balmus KJ, Nugteren Huying WM et al, Liver damage during administration of itraconazole. Ned Tijdschr Geneeskd (1993) 137: 38-41."},{"key":"CIT0150","doi-asserted-by":"crossref","unstructured":"Harm SK, Kim JB, Im S et al, Itraconazole induced acute hepatitis. Br J Dermatol (1993) 129: 500-1.","DOI":"10.1111\/j.1365-2133.1993.tb03186.x"},{"key":"CIT0151","doi-asserted-by":"crossref","unstructured":"Inman W, Kubota K, Pearce G et al, PEM Report Number 7. Itraconazole pharmaco-epidemiol. Drug Saf (1993) 2: 423-43.","DOI":"10.1002\/pds.2630020410"},{"key":"CIT0152","doi-asserted-by":"crossref","unstructured":"Nelson MR, Smith D, Erskine D et al. Ventricular fibrillation secondary to itraconazole induced hypokalemia. J Infect (1993) 26:348.","DOI":"10.1016\/0163-4453(93)96203-3"},{"key":"CIT0153","unstructured":"Costa I, Castanet J, Lacour JP et al, Vertigo and hypokalemia; two rare side effects of itraconazole. Therapie (1994) 49:149 (in French)."},{"key":"CIT0154","doi-asserted-by":"crossref","unstructured":"Rosen T, Debilitating edema associated with itraconazole therapy. Arch Dermatol (1994) 130:260-1.","DOI":"10.1001\/archderm.130.2.260"},{"key":"CIT0155","doi-asserted-by":"crossref","unstructured":"Haymen WR, Monders SM, Itraconazole induced acute generalized exanthemic pustulosis. J Am Acad Dermatol (1995) 33:130-1.","DOI":"10.1016\/0190-9622(95)90038-1"},{"key":"CIT0156","doi-asserted-by":"crossref","unstructured":"Cleveland KO, Campbell JW, Hallucinations associated with itraconazole therapy. Clin Infect Dis (1995) 21:456.","DOI":"10.1093\/clinids\/21.2.456"},{"key":"CIT0157","doi-asserted-by":"crossref","unstructured":"Ahmad SR, Singer SJ, Leissa BG, Congestive heart failure associated with itraconazole. Lancet (2001) 357:1766-7.","DOI":"10.1016\/S0140-6736(00)04891-1"},{"key":"CIT0158","doi-asserted-by":"crossref","unstructured":"Todd P, Halpern S, Munro DD, Oral terbinafine and erythema multiform. Clin Exp Dermatol (1995) 20:247-8.","DOI":"10.1111\/j.1365-2230.1995.tb01314.x"},{"key":"CIT0159","doi-asserted-by":"crossref","unstructured":"McGregor JM, Rustin MH, Terbinafine and erythema multiforme. Br J Dermatol (1994) 131: 587-8.","DOI":"10.1111\/j.1365-2133.1994.tb08573.x"},{"key":"CIT0160","doi-asserted-by":"crossref","unstructured":"White SI, Bowen-Jones D, Toxic epidermal necrolysis induced by terbinafine in a patient on long-term antiepileptics. Br J Dermatol (1996) 134:188-9.","DOI":"10.1111\/j.1365-2133.1996.tb07872.x"},{"key":"CIT0161","doi-asserted-by":"crossref","unstructured":"Carstens J, Wendelboe P, Sogaard H et al, Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereal (1994) 74: 391-2.","DOI":"10.2340\/0001555574391392"},{"key":"CIT0162","doi-asserted-by":"crossref","unstructured":"Bonsmann G, Schiller M, Luger TA et al, Terbinafine induced sub-acute cutaneous lupus erythematosis. J Am Acad Dermatol (2001) 44:925-31.","DOI":"10.1067\/mjd.2001.114565"},{"key":"CIT0163","doi-asserted-by":"crossref","unstructured":"Lazaros GA, Papatheodoridis GV, Delladetsima JK et al, Terbinafine induced cholestatic liver disease. J Hepatol (1996) 24:753-6.","DOI":"10.1016\/S0168-8278(96)80273-X"},{"key":"CIT0164","unstructured":"Vantaux P, Grasset D, Nougue J et al, Acute hepatitis related to the ingestion of terbinafine. Gastroenterol Clin Biol (1996) 20:402-3 (letter)."},{"key":"CIT0165","unstructured":"Boldewijn OY, Ottervanger JP, Mostart CM et al, Hepatitis attributed to the use of terbinafine. Ned Tijdschr voor-cEneeskucide (1996) 140:669-72."},{"key":"CIT0166","unstructured":"Shiloah E, Horowiz M, Zeder E, Terbinafine induced cholestatic liver injury. Harefuah (1997) 133:11-12,80-1."},{"key":"CIT0167","doi-asserted-by":"crossref","unstructured":"Dwyer CM, White MI, Sinclair TS, Cholestatic jaundice due to terbinafine. Br J Dermatol (1997) 136:976-7.","DOI":"10.1111\/j.1365-2133.1997.tb03954.x"},{"key":"CIT0168","unstructured":"Vivas S, Rodrigue M, Palecio MA et al, Acute hepatitis associated with terbinafine. Gastroenterol Hepatol (1997) 20:456-8."},{"key":"CIT0169","doi-asserted-by":"crossref","unstructured":"Gupta AK, Sibbald RG, Knowles SR et al, Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation; four case reports and a review of drug induced psoriasis. J Am Acad Dermatol (1997) 36:858-62.","DOI":"10.1016\/S0190-9622(97)70041-0"},{"key":"CIT0170","doi-asserted-by":"crossref","unstructured":"Smith EB, Stein LF, Fivenson DP et al, Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multi-centre trial in onychomycosis of feet. Int J Dermatol (2000) 39:861-4.","DOI":"10.1046\/j.1365-4362.2000.00087-2.x"},{"key":"CIT0171","unstructured":"Dubois D, Cost effectiveness of antifungal therapy; preliminary results of an economic evaluation of itraconazole in the treatment of onychomycosis. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy; 28-29 September 1995; pp. 38-40."},{"key":"CIT0172","doi-asserted-by":"crossref","unstructured":"Van Doorslaer EKA, Tormans G, Gupta AK et al, Economic evaluation of anti fungal agents in the treatment of toe nail onychomycosis in Germany. Dermatology (1996) 193:239-44.","DOI":"10.1159\/000246254"},{"key":"CIT0173","doi-asserted-by":"crossref","unstructured":"Marchetti A, Piech CT, Mc Ghan WF et al, Pharmaco-economic analysis of oral therapies for onychomycosis: a US Model. Clin Ther (1996) 18: 757-77.","DOI":"10.1016\/S0149-2918(96)80225-6"},{"key":"CIT0174","doi-asserted-by":"crossref","unstructured":"Gupta AK, Lambert J, Pharmaco-economic analysis of the new oral antifungal agents used to treat toenail onychomychosis in the USA. Int J Dermatol (1999) 38: 53-64.","DOI":"10.1046\/j.1365-4362.1999.00012.x"},{"key":"CIT0175","doi-asserted-by":"crossref","unstructured":"Gupta AK, DelRosso JQ. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycosis with the oral antifungal. Int J Dermatol (2000) 39:401-11.","DOI":"10.1046\/j.1365-4362.2000.00964.x"},{"key":"CIT0176","doi-asserted-by":"crossref","unstructured":"Monahan BP, Ferguson CL, Killeavy ES et al, Torsades de pointes occurring in association with terfenadine use. JAMA (1990) 264:2788-90.","DOI":"10.1001\/jama.264.21.2788"},{"key":"CIT0177","doi-asserted-by":"crossref","unstructured":"Varhe A, Olkkola KT, Neuvonen PJ, Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol (1996) 41: 319-23.","DOI":"10.1046\/j.1365-2125.1996.03189.x"},{"key":"CIT0178","doi-asserted-by":"crossref","unstructured":"Tailor SA, Gupta AK, Walker SE et al, Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol (1996) 132:350-2.","DOI":"10.1001\/archderm.132.3.350"},{"key":"CIT0179","doi-asserted-by":"crossref","unstructured":"Jalava KM, Olkkola KT, Neuvonen PJ, Itraconazole greatly increases plasma concentration and effects of felodipine. Clin Pharmacol Ther (1997) 61:410-15.","DOI":"10.1016\/S0009-9236(97)90191-0"},{"key":"CIT0180","doi-asserted-by":"crossref","unstructured":"Segaert MF, De Soete C, Vandewiele I et al, Drug interaction induced rhabdomyolysis. Nephrol Did Transplant (1996) 11:1846-7.","DOI":"10.1093\/oxfordjournals.ndt.a027682"},{"key":"CIT0181","doi-asserted-by":"crossref","unstructured":"Partanen J, Jalava K-M, Neuvonen PJ, Itraconazole increases serum digoxin concentration. Pharmacol Toxicol (1996) 79:274-6.","DOI":"10.1111\/j.1600-0773.1996.tb00273.x"},{"key":"CIT0182","doi-asserted-by":"crossref","unstructured":"Rex J, Itraconazole-digoxin interaction. Ann Intern Med (1992) 116:525.","DOI":"10.7326\/0003-4819-116-6-525"},{"key":"CIT0183","doi-asserted-by":"crossref","unstructured":"Bickers DR, Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol (1994) 31:S87-S90.","DOI":"10.1016\/S0190-9622(08)81276-5"},{"key":"CIT0184","doi-asserted-by":"crossref","unstructured":"Katz HI, Systemic antifungal agents used to treat onychomycosis. J Am Acad Dermatol (1998) 38: S48-S52.","DOI":"10.1016\/S0190-9622(98)70484-0"}],"container-title":["Journal of Dermatological Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546630305541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T14:48:45Z","timestamp":1704984525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546630305541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,1]]},"references-count":184,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1,1]]}},"alternative-id":["10.1080\/09546630305541"],"URL":"https:\/\/doi.org\/10.1080\/09546630305541","relation":{},"ISSN":["0954-6634","1471-1753"],"issn-type":[{"value":"0954-6634","type":"print"},{"value":"1471-1753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,1]]}}}